Leukemia

Charles A. Schiffer, MD, reviews clinical trial data for asciminib in chronic myeloid leukemia and highlights financial toxicity concerns.

The expert panel discusses the potential role of olverembatinib in the chronic myeloid leukemia treatment landscape.

Medical expert discusses that when managing relapsed or refractory chronic lymphocytic leukemia, the goals are similar to first-line therapy, and he emphasizes using BCL-2 and BTK inhibitors, guided by factors such as previous therapies, patient preferences, and comorbidities.

Experts discuss the management of a patient with chronic lymphocytic leukemia who experienced adverse effects such as joint pain and atrial fibrillation while on treatment with ibrutinib, emphasizing the role of cardio-oncology and considering a switch to a second-generation BTK inhibitor for better safety and fewer drug interactions.

CB-012 is set to be investigated as part of the phase 1 AMpLify trial in patients with relapsed/refractory acute myeloid leukemia.

A phase 1 study will evaluate TERN-701’s safety, efficacy, and pharmacokinetics in a population diagnosed with chronic myeloid leukemia.

Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

UT Southwestern and Mayo Clinic debated over current treatment options in chronic myeloid leukemia and multiple myeloma.

Key opinion leaders detail strategies for patients with chronic lymphocytic leukemia relapsing after fixed-duration BTK and BCL2 inhibitor treatment, emphasizing the importance of genetic testing for mutations that could render them resistant to a re-challenge and considering third-generation BTK inhibitors if mutations are found.

Ricardo Parrondo, MD, discusses the potential of combining BTK and BCL2 inhibitors in chronic lymphocytic leukemia treatment, emphasizing their synergistic effect and cautioning against use in frail patients or those with cardiovascular comorbidities, while Pooja Advani, MBBS, MD, stresses the importance of medical history and risk stratification, especially regarding cardiovascular adverse effects.

Fred Hutch and City of Hope "Face Off" regarding presentations focusing on multiple myeloma and chronic myeloid leukemia.

Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.

A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.

Experts discuss that although first-generation BTK inhibitors such as ibrutinib were groundbreaking for CLL treatment, the field is now shifting toward second-generation options because of their better toxicity profiles. However, the choice between second-generation inhibitors should be personalized, considering individual patient profiles and adverse effects.

Experts highlight that second-generation BTK inhibitors offer improved toxicity profiles, lower cardiovascular risks, and are well tolerated for long-term CLL treatment.

Investigators report that bendamustine/rituximab debulking appears to decrease tumor lysis syndrome risk in patients with previously untreated chronic lymphocytic leukemia.

Data from a phase 1 study support the orphan drug designation for SLS009 as a treatment for patients with acute myeloid leukemia.

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.

Patients receiving ibrutinib plus venetoclax for chronic lymphocytic leukemia appear to experience improved overall survival at 46 months compared with those receiving chlorambucil plus obinutuzumab in the phase 3 GLOW study.

SEQUOIA trial data show significant benefits in progression-free survival for patients with chronic lymphocytic leukemia treated with single-agent zanubrutinib, even without a high-risk 17P mutation; Pooja Advani, MD, MBBS, notes that second-generation BTK inhibitors show lower rates of atrial fibrillation and flutter compared with first-generation ones, suggesting increased cardiac safety.

Ricardo D. Parrondo, MD, discusses monotherapy and combination BTKi therapy options for chronic lymphocytic leukemia, noting that the decision depends on patient preferences and disease risk.

Expert insight into the later-line efficacy and tolerability of olverembatinib, a third generation TKI, in ponatinib-resistant, refractory chronic myeloid leukemia populations.

Results from the phase 3 COG ALL1331 trial found the use of blinatumomab for pediatric patients with B-cell acute lymphoblastic leukemia improved efficacy.

Based on findings from the phase 1/2 BCHILD trial, the FDA approved bosutinib for pediatric chronic myelogenous leukemia.